24 results on '"Eriksson, Olof"'
Search Results
2. O-39 - Non-invasive imaging of neutrophils in acute sepsis.
- Author
-
Wilske, Frida, Eriksson, Olof, Sigfridsson, Jonathan, Janols, Helena, Skorup, Paul, Khalil, Amina, Roslin, Sara, Lipcsey, Miklos, Castegren, Markus, and Antoni, Gunnar
- Subjects
- *
NEUTROPHILS , *SEPSIS - Published
- 2023
- Full Text
- View/download PDF
3. P-026 - PET imaging of lung inflammation in pig by neutrophil elastase inhibitor [11C]GW457427.
- Author
-
Eriksson, Olof, Puuvuori, Emmi, Chiodaroli, Elena, Liggieri, Francesco, Sigfridsson, Jonathan, Romelin, Hampus, Ingvast, Sofie, Estrada, Sergio, Elgland, Mathias, Cheung, Pierre, Korsgren, Olle, Perchiazzi, Gaetano, and Antoni, Gunnar
- Subjects
- *
LEUCOCYTE elastase , *POSITRON emission tomography , *ELASTASES , *PNEUMONIA , *SWINE , *LUNGS - Published
- 2022
- Full Text
- View/download PDF
4. 5-Fluoro-[β-11C]-L-tryptophan is a functional analogue of 5-hydroxy-[β-11C]-L-tryptophan in vitro but not in vivo.
- Author
-
Eriksson, Olof, Selvaraju, Ramkumar, Borg, Beatrice, Asplund, Veronika, Estrada, Sergio, and Antoni, Gunnar
- Subjects
- *
TRYPTOPHAN , *IN vitro studies , *POSITRON emission tomography , *NEUROENDOCRINE tumors , *RADIOISOTOPES , *CARBON isotopes , *LABORATORY mice , *XENOGRAFTS - Abstract
Abstract: Introduction: 5-Hydroxy-[β-11C]-L-tryptophan ([11C]HTP) is an established positron emission tomography (PET) imaging agent for neuroendocrine tumors (NETs). It has also been used for other clinical research purposes in neurology and diabetes. However, its widespread use is limited by the short physical half-life of the radionuclide and a difficult radiosynthesis. Therefore, a Fluorine-18 labeled analogue, 5-[18F]Fluoro-L-tryptophan ([18F]FTRP), has been proposed as a functional analogue. There is no published method for the synthesis of L-[18F]FTRP. We have therefore developed a synthesis of 5-fluoro-[β-11C]-L-tryptophan ([11C]FTRP), based on the existing chemo-enzymatic method for [11C]HTP and evaluated the potential usefulness of radiolabeled FTRP as a substitute for [11C]HTP. Methods: The in vitro and in vivo behavior of [11C]FTRP, including the dependence of key enzymes in the serotonergic metabolic pathway, was investigated in NET cell lines, NET xenograft carrying immunodeficient mice, normal rats and in non-human primate. [11C]HTP was used for direct comparison. Results: Uptake of [11C]FTRP in NET cell lines in vitro was mediated by enzymes involved in serotonin synthesis and metabolism, similar to [11C]HTP. In vivo biodistribution, either in rodent or non-human primate, was not affected by selectively inhibiting enzymatic steps in the serotonergic metabolic pathway. Conclusion: [11C]FTRP has in vitro biological function similar to that of [11C]HTP. However, this function is not retained in vivo as shown by biodistribution and PET/CT studies. Radiolabeled FTRP is thus not likely to provide an advantage over [11C]HTP in PET imaging in oncology, neurology or diabetes. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
5. Preclinical evaluation of a 68Ga-labeled biotin analogue for applications in islet transplantation
- Author
-
Eriksson, Olof, Carlsson, Fredrik, Blom, Elisabeth, Sundin, Anders, Långström, Bengt, Korsgren, Olle, and Velikyan, Irina
- Subjects
- *
ISLANDS of Langerhans transplantation , *RADIOLABELING , *BIOTIN , *TREATMENT of diabetes , *TYPE 1 diabetes , *DIAGNOSTIC imaging , *POSITRON emission tomography , *LABORATORY mice , *BIOCONJUGATES - Abstract
Abstract: Introduction: Islet transplantation is a promising treatment for type 1 diabetes mellitus, but the fate of the cells after intraportal infusion is unclear. It is therefore imperative to develop novel techniques for noninvasive imaging and quantification of events following islet transplantation. Methods: Small islet-like microbeads, avidin-covered agarose resins (AARs), were used as a model system for islet transplantation. Capability for specific [68Ga]Ga-DOTA-(PEG)2-biotin uptake and retention for either AARs or human islets conjugated with avidin by means of a heparin scaffold was studied in vitro. Biodistribution of the novel positron emission tomography (PET) tracer [68Ga]Ga-DOTA-(PEG)2-biotin was evaluated in mice treated by intraportal transplantation of AARs by μPET/computed tomography and ex vivo organ distribution and compared with control mice. Results: AARs had high capability to bind [68Ga]Ga-DOTA-(PEG)2-biotin, close to 50% of administrated tracer/μl in vitro (>0.25 MBq/μl). Avidin-tagged human islets could bind on average 2.2% of administered tracer/μl. Specificity (>90%) and retention (>90% after 1 h) were high for both AARs and avidin-tagged islets. Hepatic tracer uptake and retention were increased in mice transplanted with AARs [standardized uptake value (SUV)=2.6] compared to the untreated group (SUV=1.4). In vivo uptake of tracer to AARs was blocked by preadministration of unlabeled biotin. Conclusions: Avidin-tagged islet-like objects can be tracked in hepatic volume after intraportal transplantation by using [68Ga]Ga-DOTA-(PEG)2-biotin and PET. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
6. Distribution of adoptively transferred porcine T-lymphoblasts tracked by 18F-2-fluoro-2-deoxy-d-glucose and position emission tomography
- Author
-
Eriksson, Olof, Sadeghi, Arian, Carlsson, Björn, Eich, Torsten, Lundgren, Torbjörn, Nilsson, Bo, Tötterman, Thomas, Korsgren, Olle, and Sundin, Anders
- Subjects
- *
POSITRON emission tomography , *GLUCOSE , *FLUORINE isotopes , *LYMPHOCYTES , *RADIOLABELING , *RADIOACTIVE tracers , *LABORATORY swine - Abstract
Abstract: Introduction: Autologous or allogeneic transfer of tumor-infiltrating T-lymphocytes is a promising treatment for metastatic cancers, but a major concern is the difficulty in evaluating cell trafficking and distribution in adoptive cell therapy. This study presents a method of tracking transfusion of T-lymphoblasts in a porcine model by 18F-2-fluoro-2-deoxy-d-glucose ([18F]FDG) and positron emission tomography. Methods: T-lymphoblasts were labeled with the positron-emitting tracer [18F]FDG through incubation. The T-lymphoblasts were administered into the bloodstream, and the distribution was followed by positron emission tomography for 120 min. The cells were administered either intravenously into the internal jugular vein (n=5) or intraarterially into the ascending aorta (n=1). Two of the pigs given intravenous administration were pretreated with low-molecular-weight dextran sulphate. Results: The cellular kinetics and distribution were readily quantifiable for up to 120 min. High (78.6% of the administered cells) heterogeneous pulmonary uptake was found after completed intravenous transfusion. The pulmonary uptake was decreased either by preincubating and coadministrating the T-lymphoblasts with low-molecular-weight dextran sulphate or by administrating them intraarterially. Conclusions: The present work shows the feasibility of quantitatively monitoring and evaluating cell trafficking and distribution following administration of [18F]FDG-labeled T-lymphoblasts. The protocol can potentially be transferred to the clinical setting with few modifications. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass
- Author
-
Eriksson, Olof, Jahan, Mahabuba, Johnström, Peter, Korsgren, Olle, Sundin, Anders, Halldin, Christer, and Johansson, Lars
- Subjects
- *
PANCREATIC beta cells , *POSITRON emission tomography , *FLUOROETHYLENE , *CHEMICAL kinetics , *PEOPLE with diabetes , *CARRIER proteins - Abstract
Abstract: Introduction: The positron emission tomography (PET) tracer 9-[18F]fluoroethyl-(+)-dihydrotetrabenazine ([18F]-FE-(+)-DTBZ) is a potential candidate for quantifying beta-cell mass in vivo. The purpose was to investigate in vitro and in vivo utility of this tracer for the assessment of beta-cell mass. Methods: Three pigs were intravenously administered [18F]-FE-(+)-DTBZ and examined by PET/computed tomography. Binding parameters were estimated by kinetic modeling. In vitro k D and B max were determined by saturation binding studies of endocrine and exocrine human tissue homogenates. In vitro pancreatic uptake was determined by tissue autoradiography with pancreases from patients with types 1 (T1DM) and 2 diabetes mellitus (T2DM) and healthy controls. Results: [18F]-FE-(+)-DTBZ had a k D of 3.5±1.0 nM, a B max of 382±108 fmol/mg protein and a specificity of 89±1.8% in islet homogenates. The total exocrine uptake was lower and 65% was nondisplaceable. No uptake difference was observed in pancreatic tissue slices from patients with T1DM, T2DM or healthy controls. The in vivo porcine pancreatic uptake reached a peak of standardized uptake value (SUV) of 2.8 with a low distribution volume ratio in all animals. Moderate to high tracer uptake was identified in the bile system and in bone. Conclusions: [18F]-FE-(+)-DTBZ binds to vesicular monoamine transporter 2 (VMAT2) with high specificity in pure islet tissue in vitro. However, there is high nondisplaceable binding to exocrine tissue. In addition, in vivo tracer metabolism and dehalogenation result in severe underestimation of porcine pancreatic VMAT2 expression and BCM. The results do not support [18F]-FE-(+)-DTBZ as a suitable tracer for in vivo beta-cell imaging. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
8. Positron emission tomography and target-controlled infusion for precise modulation of brain drug concentration
- Author
-
Eriksson, Olof, Josephsson, Ray, Långstrom, Bengt, and Bergström, Mats
- Subjects
- *
POSITRON emission tomography , *COMPUTER-aided diagnosis , *DIAGNOSTIC imaging , *DRUGS - Abstract
Abstract: Introduction: There are several instances when it is desirable to control brain concentration of pharmaceuticals, e.g., to modulate the concentration of anesthetic agents to different desired levels fitting to different needs during the course of surgery. This has so far only been possible using indirect estimates of drug concentration such as assuming constant relation between tissue and blood including extrapolations from animals. Methods: A system for controlling target tissue concentration (UIPump) was used to regulate whole-brain concentrations of a central benzodiazepine receptor antagonist at therapeutic levels with input from brain kinetics as determined with PET. The system was tested by using pharmacological doses of flumazenil mixed with tracer amounts of [11C]flumazenil. Flumazenil was used as a model compound for anesthesia. An infusion scheme to produce three different steady-state levels in sequence was designed based on kinetic curves obtained after bolus injection. The subjects (Sprague-Dawley rats, n=6) were monitored in a microPET scanner during the whole experiment to verify resulting brain kinetic curves. Results: A steady-state brain concentration was rapidly achieved corresponding to a whole-brain concentration of 118±6 ng/ml. As the infusion rate decreased to lower the exposure by a factor of 2, the brain concentration decreased to 56±4 ng/ml. A third increased steady-state level of anesthesia corresponding to a whole-brain concentration of 107±7 ng/ml was rapidly achieved. Conclusion: The experimental setup with computerized pump infusion and PET supervision enables accurate setting of target tissue drug concentration. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
9. Systematic screening of imaging biomarkers for the Islets of Langerhans, among clinically available positron emission tomography tracers.
- Author
-
Karlsson, Filip, Antonodimitrakis, Pantelis Clewemar, and Eriksson, Olof
- Subjects
- *
TOMOGRAPHY , *ISLANDS of Langerhans , *RADIOSCOPIC diagnosis , *POSITRON emission , *RADIONUCLIDE imaging , *DIAGNOSTIC imaging - Abstract
Introduction Functional imaging could be utilized for visualizing pancreatic islets of Langerhans. Therefore, we present a stepwise algorithm for screening of clinically available positron emission tomography (PET) tracers for their use in imaging of the neuroendocrine pancreas in the context of diabetes. Methods A stepwise procedure was developed for screening potential islet imaging agents. Suitable PET-tracer candidates were identified by their molecular mechanism of targeting. Clinical abdominal examinations were retrospectively analyzed for pancreatic uptake and retention. The target protein localization in the pancreas was assessed in silico by –omics approaches and the in vitro by binding assays to human pancreatic tissue. Results Six putative candidates were identified and screened by using the stepwise procedure. Among the tested PET tracers, only [ 11 C]5-Hydroxy-tryptophan passed all steps. The remaining identified candidates were falsified as candidates and discarded following in silico and in vitro screening. Conclusions Of the six clinically available PET tracers identified, [ 11 C]5-HTP was found to be a promising candidate for beta cell imaging, based on intensity of in vivo pancreatic uptake in humans, and islet specificity as assessed on human pancreatic cell preparations. The flow scheme described herein constitutes a methodology for evaluating putative islet imaging biomarkers among clinically available PET tracers. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type 1.
- Author
-
Rosestedt, Maria, Velikyan, Irina, Rosenström, Ulrika, Estrada, Sergio, Åberg, Ola, Weis, Jan, Westerlund, Christer, Ingvast, Sofie, Korsgren, Olle, Nordeman, Patrik, and Eriksson, Olof
- Subjects
- *
RADIOLABELING , *TYPE 1 diabetes , *COLLAGEN , *HEPATIC fibrosis , *POSITRON emission tomography , *AUTORADIOGRAPHY - Abstract
Pathological formation of fibrosis, is an important feature in many diseases. Fibrosis in liver and pancreas has been associated to metabolic disease including type 1 and 2 diabetes. The current methods for detecting and diagnosing fibrosis are either invasive, or their sensitivity to detect fibrosis in early stage is limited. Therefore, it is crucial to develop non-invasive methods to detect, stage and study the molecular processes that drive the pathology of liver fibrosis. The peptide LRELHLNNN was previously identified as a selective binder to collagen type I with an affinity of 170 nM. Radiolabelled LRELHLNNN thus constitute a potential PET tracer for fibrosis. LRELHLNNN was conjugated to a DOTA/NOTA moiety via a PEG 2 -linker. DOTA-PEG 2 -LRELHLNNN was labelled with Gallium-68 and NOTA- PEG 2 -LRELHLNNN with aluminium fluoride-18. Biodistribution of 68Ga]Ga-DOTA-PEG 2 -LRELHLNNN and 18F]AlF-NOTA-PEG 2 -LRELHLNNN was performed in healthy rats ex vivo and in vivo. The 68Ga-labelled analogue was evaluated in a mouse model of liver fibrosis by PET/MRI-imaging. The human predicted dosimetry of the tracers was extrapolated from rat ex vivo biodistribution studies at 10, 20, 40, 60, 120, 180 min (only fluoride-18) post-injection. The peptides were successfully radiolabelled with gallium-68 and aluminium fluoride-18, respectively. The biodistribution of 68Ga]Ga-DOTA-PEG 2 -LRELHLNNN and 18F]AlF-NOTA-PEG 2 -LRELHLNNN was favorable showing rapid clearance and low background binding in organs where fibrosis may develop. Binding of 68Ga]Ga-DOTA-PEG 2 -LRELHLNNN to fibrotic liver was higher than surrounding tissues in mice with induced hepatic fibrosis. However, the binding was in the range of SUV 0.3, indicating limited targeting of the tracer to liver. The extrapolated human predicted dosimetric profiles of 68Ga]Ga-DOTA-PEG 2 -LRELHLNNN and 18F]AlF-NOTA-PEG 2 -LRELHLNNN were beneficial, potentially allowing at least three PET examinations annually. We describe the modification, radiolabelling and evaluation of the collagen type I binding peptide LRELHLNNN. The resulting radiotracer analogues demonstrated suitable biodistribution and dosimetry. 68Ga]Ga-DOTA-PEG 2 -LRELHLNNN exhibited binding to hepatic fibrotic lesions and is a promising tool for PET imaging of fibrosis. Validation of a new collagen targeting PET tracer. Early, non-invasive diagnosis and stratification of fibrosis in order to improve the diagnosis, staging and treatment of patients with diseases involving fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor.
- Author
-
Khalil, Amina, Hakhverdyan, Sona, Cheung, Pierre, Bossart, Martin, Wagner, Michael, Eriksson, Olof, and Velikyan, Irina
- Subjects
- *
AMINO acid residues , *C-terminal residues , *PEPTIDES , *POLYACRYLAMIDE gel electrophoresis , *GLUCAGON receptors , *BLOOD plasma , *AMINO acids , *FATTY acids - Abstract
The beneficial role of glucose-dependent insulinotropic polypeptide receptor (GIPR) in weight control and maintaining glucose levels has led to the development of several multi-agonistic peptide drug candidates, targeting GIPR and glucagon like peptide 1 receptor (GLP1R) and/or the glucagon receptor (GCGR). The in vivo quantification of target occupancy by these drugs would accelerate the development of new drug candidates. The aim of this study was to evaluate a novel peptide (GIP1234), based on previously reported ligand DOTA-GIP-C803, modified with a fatty acid moiety to prolong its blood circulation. It would allow higher target tissue exposure and consequently improved peptide uptake as well as in vivo PET imaging and quantification of GIPR occupancy by novel drugs of interest. A 40 amino acid residue peptide (GIP1234) was synthesized based on DOTA-GIP-C803, in turn based on the sequences of endogenous GIP and Exendin-4 with specific amino acid modifications to obtain GIPR selectivity. A palmitoyl fatty acid chain was furthermore added at Lys14 via a glutamic acid linker to prolong its blood circulation time by the interaction with albumin. GIP1234 was conjugated with a DOTA chelator at the C-terminal cysteine residue to achieve 68Ga radiolabeling. The resulting PET probe, [68Ga]Ga-DOTA-GIP1234 was evaluated for receptor binding specificity and selectivity using HEK293 cells transfected with human GIPR, GLP1R, or GCGR. Blocking experiments with tirzepatide (2 μM) were conducted using huGIPR HEK293 cells to investigate binding specificity. Ex vivo and in vivo organ distribution of [68Ga]Ga-DOTA-GIP1234 was studied in rats and a pig in comparison to [68Ga]Ga-DOTA-C803-GIP. Binding of [68Ga]Ga-DOTA-GIP1234 to albumin was assessed in situ using polyacrylamide gel electrophoresis (PAGE). The stability was tested in formulation buffer and rat blood plasma. [68Ga]Ga-DOTA-GIP1234 was synthesized with non-decay corrected radiochemical yield of 88 ± 3.7 % and radiochemical purity of 97.8 ± 0.8 %. The molar activity for the radiotracer was 8.1 ± 1.1 MBq/nmol. [68Ga]Ga-DOTA-GIP1234 was stable and maintained affinity to huGIPR HEK293 cells (dissociation constant (K d) = 40 ± 12.5 nM). The binding of [68Ga]Ga-DOTA-GIP1234 to huGCGR and huGLP1R cells was insignificant. Pre-incubation of huGIPR HEK293 cell sections with tirzepatide resulted in the decrease of [68Ga]Ga-DOTA-GIP1234 binding by close to 90 %. [68Ga]Ga-DOTA-GIP1234 displayed slow blood clearance in pigs with SUV = 3.5 after 60 min. Blood retention of the tracer in rat was 2-fold higher than that of [68Ga]Ga-DOTA-C803-GIP. [68Ga]Ga-DOTA-GIP1234 also demonstrated strong liver uptake in both pig and rat combined with decreased renal excretion. The concentration dependent binding of [68Ga]Ga-DOTA-GIP1234 to albumin was confirmed in situ by PAGE. [68Ga]Ga-DOTA-GIP1234 demonstrated nanomolar affinity and selectivity for huGIPR in vitro. Addition of a fatty acid moiety prolonged blood circulation time and tissue exposure in both rat and pig in vivo. However, the liver uptake was also increased which may make PET imaging of abdominal tissues such as pancreas challenging. The investigation of the influence of fatty acid moiety on the biological performance of the peptide ligand paved the way for further rational design of GIPR ligand analogues with improved characteristics. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. P-195 - Non-invasive assessment of fibrogenesis by PET imaging using a [Al18F]RESCA-Affibody molecule targeting PDGFRβ.
- Author
-
Wegrzyniak, Olivia, Lechi, Francesco, Zhang, Bo, Mitran, Bogdan, Cheung, Pierre, Bitzios, Athanasios, Hulsart-Billström, Gry, Persson, Jonas, Lofblom, John, Nordström, Helena, Eriksson, Jonas, Frejd, Fredrik, Korsgren, Olle, and Eriksson, Olof
- Subjects
- *
MOLECULES - Published
- 2023
- Full Text
- View/download PDF
13. P-196 - Occupancy of Glucagon Like Peptide-1 receptor by Tirzepatide and SAR441255 measured with [68Ga]Ga-DO3A-exendin-4/PET in vivo.
- Author
-
Khalil, Amina, Velikyan, Irina, Bossart, Martin, Wagner, Michael, and Eriksson, Olof
- Subjects
- *
GLUCAGON , *MEASUREMENT - Published
- 2023
- Full Text
- View/download PDF
14. P-190 - [68Ga]Ga-DOTA-GIP1234 for PET imaging of glucose-dependent insulinotropic polypeptide receptor (GIPR).
- Author
-
Khalil, Amina, Velikyan, Irina, Hakhverdyan, Sona, Cheung, Pierre, Bossart, Martin, Wagner, Michael, and Eriksson, Olof
- Published
- 2023
- Full Text
- View/download PDF
15. P-187 - [18F]MK-7246 for Positron Emission Tomography imaging of beta cells surface marker GRP44.
- Author
-
Cheung, Pierre, Amin, Mohammad, Zhang, Bo, Lechi, Francesco, Korsgren, Olle, Eriksson, Jonas, Odell, Luke R., and Eriksson, Olof
- Subjects
- *
POSITRON emission tomography , *CELL imaging , *PANCREATIC beta cells , *FIDUCIAL markers (Imaging systems) - Published
- 2023
- Full Text
- View/download PDF
16. Synthesis and preclinical evaluation of the CRTH2 antagonist [11C]MK-7246 as a novel PET tracer and potential surrogate marker for pancreatic beta-cell mass.
- Author
-
Eriksson, Jonas, Roy, Tamal, Sawadjoon, Supaporn, Bachmann, Kim, Sköld, Christian, Larhed, Mats, Weis, Jan, Selvaraju, Ram Kumar, Korsgren, Olle, Eriksson, Olof, and Odell, Luke R.
- Subjects
- *
PANCREATIC beta cells , *BIOMARKERS , *TYPE 2 diabetes , *RADIOCHEMICAL purification , *TYPE 1 diabetes , *ISLANDS of Langerhans - Abstract
MK-7246 is a potent and selective antagonist for chemoattractant receptor-homologous molecule expressed on T h 2 cells (CRTH2). Within the pancreas CRTH2 is selectively expressed in pancreatic β-cells where it is believed to play a role in insulin release. Reduction in β-cell mass and insufficient insulin secretion in response to elevated blood glucose levels is a hallmark for type 1 and type 2 diabetes. Reported here is the synthesis of [11C]MK-7246 and initial preclinical evaluation towards CRTH2 imaging. The aim is to develop a method to quantify β-cell mass with PET and facilitate non-invasive studies of disease progression in individuals with type 2 diabetes. The precursor N -desmethyl- O -methyl MK-7246 was synthesized in seven steps and subjected to methylation with [11C]methyl iodide followed by hydrolysis to obtain [11C]MK-7246 labelled in the N -methyl position. Preclinical evaluation included in vitro radiography and immune-staining performed in human pancreatic biopsies. Biodistribution studies were performed in rat by PET-MRI and in pig by PET-CT imaging. Saturable tracer binding was examined in pig by scanning before and after administration of MK-7246 (1 mg/kg). Predicted dosimetry of [11C]MK-7246 in human males was estimated based on the biodistribution in rat. [11C]MK-7246 was obtained with activities sufficient for the current investigations (270 ± 120 MBq) and a radiochemical purity of 93 ± 2%. The tracer displayed focal binding in areas with insulin positive islet of Langerhans in human pancreas sections. Baseline uptake in pig was reduced in tissues with known expression of CRTH2 after administration of MK-7246; pancreas (66% reduction) and spleen (88% reduction). [11C]MK-7246 exhibited a safe human predicted dosimetry profile as extrapolated from the rat biodistribution data. Initial preclinical in vitro and in vivo evaluations of [11C]MK-7246 show binding and biodistribution properties suitable for PET imaging of CRTH2. Further studies are warranted to assess its potential in β-cell mass imaging and CRTH2 drug development. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs.
- Author
-
Rydén, Anneli, Nyman, Görel, Nalin, Lovisa, Andreasson, Susanne, Korsgren, Olle, Eriksson, Olof, and Jensen-Waern, Marianne
- Subjects
- *
INTRAVENOUS therapy complications , *CARDIOVASCULAR agents , *DRUG side effects , *DRUG administration , *INSULIN therapy , *EXENDINS , *RADIOLABELING , *LABORATORY swine - Abstract
Introduction Radiolabeled Exendin-4, a synthetic glucagon-like peptide-1 (GLP-1) analog, is used as a tracer for diagnostic purposes of β-cells and in experimental animal research. Exendin-4 can be radiolabeled with 68 Ga, 111 In or 99m Tc and used for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging to diagnose insulinomas, visualization of pancreatic β-cell mass and transplanted Islets of Langerhans. In humans, Exendin-4 is widely used as a therapeutic agent for treatment of type 2 diabetes (T2D). The compound, which is administered subcutaneously (SC) may cause nausea, vomiting and a minor increase in the heart rate (HR). However, possible side-effects on cardiovascular functions after intravenous (IV) administration have not been reported. This study describes the Exendin-4 dose at which cardiovascular side-effects occur in pigs and cynomolgus monkeys. The IV effect of the tracer on insulin secretion is also investigated in pigs. Methods Seven clinically healthy littermate pigs (40 days old) were used; three of them were made diabetic by streptozotocin (STZ). All pigs underwent PET imaging under general anesthesia to examine the glucagon-like peptide-1 receptor (GLP-1R) in β-cells with radiolabeled Exendin-4. A baseline tracer dose IV [ 68 Ga]Exendin-4 (0.025 ± 0.010 μg/kg) followed by a competition dose IV [ 68 Ga]Exendin-4 (3.98 ± 1.33 μg/kg) 60 min later were administered. Blood samples were taken and analyzed for insulin secretion by using ELISA. Cardiovascular and respiratory variables were monitored throughout the experiment. Results Immediately after administration of the high dose [ 68 Ga]Exendin-4 the HR rose from 122 ± 14 to 227 ± 40 bpm (p < 0.01) and from 100 ± 5 to 181 ± 13 bpm (p < 0.01) in healthy non-diabetic and diabetes-induced pigs, respectively. The tachycardia was observed for > 2 h and one healthy non-diabetic pig suffered cardiac arrest 3 h after the IV [ 68 Ga]Exendin-4. Arrhythmia was detected by listening to the heart with a stethoscope up to 4 days after the [ 68 Ga]Exendin-4 injection. In all animals, no effect on the cardiovascular system was registered after the low dose of IV [ 68 Ga]Exendin-4. Insulin secretion increased (p < 0.05) when IV [ 68 Ga]Exendin-4 was given in dosages ≥ 0.14 μg/kg. Conclusions Intravenous administration of ≥ 2.8 μg/kg [ 68 Ga]Exendin-4 resulted in severe tachycardia and arrhythmias in healthy non-diabetic and diabetes-induced pigs, and the insulin secretion was stimulated in healthy non-diabetic animals when ≥ 0.14 μg/kg [ 68 Ga]Exendin-4 was given. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. P-118 - Synthesis of fluorine-18 labelled tetrazine and coupling to trans-cyclooctene functionalized Affibody molecules.
- Author
-
Zhang, Bo, Rokka, Johanna, Lechi, Francesco, Eriksson, Olof, and Eriksson, Jonas
- Subjects
- *
TETRAZINE , *MOLECULES - Published
- 2022
- Full Text
- View/download PDF
19. P-022 - Immune mediated inflammation and perfusion in lungs of Covid-19 patients studied with [11C]GW457427 and [15O]water: a first-in-man pilot study.
- Author
-
Antoni, Gunnar, Sorensen, Jens, Lubberink, Mark, Lindström, Elin, Elgland, Mathias, Eriksson, Olof, Hultström, Michael, Frithiof, Robert, Wanhainen, Anders, Sigfridsson, Jonathan, Skorup, Paul, and Lipcsey, Miklos
- Subjects
- *
COVID-19 , *PNEUMONIA , *PILOT projects , *LUNGS - Published
- 2022
- Full Text
- View/download PDF
20. O-67 - Evaluation of Affibody molecule Z09591 for PET imaging in fibrosis.
- Author
-
Wegrzyniak, Olivia, Rokka, Johanna, Zhang, Bo, Rosestedt, Maria, Cheung, Pierre, Mitran, Bogdan, Ingvast, Sofie, Puuvuori, Emmi, Pontén, Fredrik, Frejd, Fredrik, Korsgren, Olle, Eriksson, Jonas, and Eriksson, Olof
- Subjects
- *
POSITRON emission tomography , *FIBROSIS , *MOLECULES - Published
- 2022
- Full Text
- View/download PDF
21. O-60 - Development of peptide probes for imaging of CD206 positive macrophages in cancer.
- Author
-
Zhang, Bo, Cheung, Pierre, Amin, Mohammad, Odell, Luke R., Korsgren, Olle, Eriksson, Olof, and Eriksson, Jonas
- Subjects
- *
PEPTIDES , *MACROPHAGES , *DNA probes - Published
- 2022
- Full Text
- View/download PDF
22. Synthesis and preclinical evaluation of 68Ga-labeled collagelin analogs for imaging and quantification of fibrosis.
- Author
-
Velikyan, Irina, Rosenström, Ulrika, Estrada, Sergio, Ljungvall, Ingrid, Häggström, Jens, Eriksson, Olof, and Antoni, Gunnar
- Subjects
- *
FIBROSIS , *GALLIUM isotopes , *CHEMICAL synthesis , *ACETIC acid , *AUTORADIOGRAPHY , *PHARMACOKINETICS , *DIAGNOSIS - Abstract
Objectives Fibrosis affecting functionality of vital organs such as liver, lung, heart, and kidney, is involved in many chronic diseases. Positron emission tomography (PET) would not only provide precise localization and extent of the affected tissue but also allow the accurate quantification of the fibrotic process for the subsequent prognosis. Methods A cyclic peptide c[CPGRVMHGLHLGDDEGPC] conjugated either to 2-(4,7-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7-triazonan-1-yl)acetic acid (NOTA(tBu) 2 ) or 4-(4,7-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7-triazacyclononan-1-yl)-5-(tert-butoxy)-5-oxopentanoic acid (NODAGA(tBu) 3 ) via polyethylene glycol link (PEG 2 ) was synthesized and labeled with 68 Ga. Non-specific organ distribution, blood clearance, and excretion were investigated ex vivo in healthy rats. The binding specificity of the radioligands was assessed in vitro using autoradiography on cryosections of dog fibrotic heart tissue. Results The yield of NOTA-PEG 2 -c[CPGRVMHGLHLGDDEGPC] and NODAGA-PEG 2 -c[CPGRVMHGLHLGDDEGPC] was 56% and 41%, respectively. Non-decay-corrected radiochemical yield was 80 ± 5% with radiochemical purity of 95 ± 4%. Pharmacokinetic studies in healthy male Sprague–Dawley rats showed fast blood clearance and renal excretion. Lower uptake in liver, spleen, and kidney was found for [[ 68 Ga]Ga-NOTA] + 1 -PEG 2 -c[CPGRVMHGLHLGDDEGPC] as compared to [[ 68 Ga]Ga-NODAGA] 0 -PEG 2 -c[CPGRVMHGLHLGDDEGPC]. Histologic evaluation of the left ventricle (LV) myocardium from a dog with severe mitral regurgitation (MR), revealed mild to moderate perivascular and subendocardial, and mild diffuse interstitial fibrosis. The tracer binding to the cryosections of the tissue was specific with the equilibrium Kd of 2.3 ± 0.8 μM and 2.1 ± 0.9 μM, respectively for [ 68 Ga]Ga-NO2A-Col and [ 68 Ga]Ga-NODAGA-Col. Conclusions Two novel peptide based agents for the imaging of fibrosis by PET were developed. Moderation of the biodistribution could be achieved by variation of the charge on the complex moiety of the agents. The combination of the fast clearance from non-target organs as well as organs of interest such as lung, heart, and liver and binding specificity to the target tissue suggests the potential of the analogs for the imaging of fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Pre-clinical evaluation of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma.
- Author
-
Selvaraju, Ram Kumar, Velikyan, Irina, Asplund, Veronika, Johansson, Lars, Wu, Zhanhong, Todorov, Ivan, Shively, Jack, Kandeel, Fouad, Eriksson, Barbro, Korsgren, Olle, and Eriksson, Olof
- Subjects
- *
INSULINOMA , *AUTORADIOGRAPHY , *HYPERINSULINISM , *EXENDINS , *POSITRON emission tomography , *GLUCAGON-like peptide 1 , *LABORATORY mice , *EVALUATION of clinical trials - Abstract
Abstract: Introduction: Insulinoma is the most common form of pancreatic endocrine tumors responsible for hyperinsulinism in adults. These tumors overexpress glucagon like peptide-1 (GLP-1) receptor, and biologically stable GLP-1 analogs have therefore been proposed as potential imaging agents. Here, we evaluate the potential of a positron emission tomography (PET) tracer, [68Ga]Ga-DO3A-VS-Cys40-Exendin-4, for imaging and quantification of GLP-1 receptors (GLP-1R) in insulinoma. Methods: [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 was evaluated for binding to GLP-1R by in vitro autoradiography binding studies in INS-1 tumor from xenografts. In vivo biodistribution was investigated in healthy control mice, INS-1 xenografted and PANC1 xenografted immunodeficient mice at two different doses of peptide: 2.5μg/kg (baseline) and 100μg/kg (block). In vivo imaging of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 in xenografted mice was evaluated by small animal PET/CT using a direct comparison with the clinically established insulinoma marker [11C]5-hydroxy-tryptophan ([11C]5-HTP). Results: GLP-1 receptor density could be quantified in INS-1 tumor biopsies. [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 showed significant uptake (p≤0.05) in GLP1-R positive tissues such as INS-1 tumor, lungs and pancreas upon comparison between baseline and blocking studies. In vivo imaging showed concordant results with higher tumor-to-muscle ratio in INS-1 xenografted mice compared with [11C]5-HTP. Conclusion: [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 has high affinity and specificity for GLP-1R expressed on insulinoma in vitro and in vivo. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
24. Corrigendum to “Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs” [Nucl Med Biol 43 (2016) 397–402].
- Author
-
Rydén, Anneli, Nyman, Görel, Nalin, Lovisa, Andreasson, Susanne, Velikyan, Irina, Korsgren, Olle, Eriksson, Olof, and Jensen-Waern, Marianne
- Subjects
- *
EXENDINS , *INSULIN - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.